iX Biopharma narrows losses in H1 FY 2026 despite 14% fall in revenue

Net loss narrowing to $2.1m, compared with a loss of $6.3m in 1H FY 2025.

iX Biopharma Ltd. reported improved earnings performance for the six months ended December 31, 2025, despite a year-on-year decline in revenue.

For the first half of FY 2026, the Group posted revenue of $3.2m, a 14% decrease from $3.7m recorded in the same period a year earlier.

The decline was offset by a significant reduction in losses, with net loss narrowing to $2.1m, compared with a loss of $6.3m in H1 FY 2025. Loss per share improved to $0.0023, from $0.0072 previously.

The Group’s balance sheet strengthened during the period, with total equity and net asset value rising to $4.1m, up sharply from $365,00p as of 30 June.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia